文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

实验室警报指导外科患者早期重症监护团队复查:一项可行性、安全性和有效性初步随机对照试验

Laboratory alerts to guide early intensive care team review in surgical patients: A feasibility, safety, and efficacy pilot randomized controlled trial.
PubMed 文献 · Resuscitation · 2018-10-11
一句话结论在外科病房,基于常规实验室检查的警报可识别高死亡率患者,触发早期ICU团队复查与首次RRT激活增多相关,并使后续警报和RRT激活减少。

该前瞻性初步随机对照试验在外科病房纳入205例住院超过24小时的患者,使用已验证的风险评估工具对每套常规实验室检查生成「实验室警报」,将警报患者随机分为早期ICU团队复查组(103例)和常规照护组(102例)。干预组首次警报时更易触发RRT激活(10.7% vs 2.0%,P<0.001),但更少接受联合健康转诊(18.0% vs 24.5%,p=0.007);后续警报前24小时内RRT激活更少(18.4% vs 22.4%,p=0.008),进一步警报更少(204 vs 320,p<0.001),但更易在后续警报前24小时内获得不予复苏或气管插管状态(26.6% vs 17.3%,p=0.05)。24小时死亡率干预组1.9% vs 对照组2.9%(p=0.63),总死亡率19.4% vs 23.5%(p=0.50)。作者结论认为实验室警报可识别高死亡率外科患者,警报触发的干预与更多首次警报相关RRT激活、更多向保守复苏状态转变、更少后续警报相关RRT激活、更少后续警报及更少联合健康干预相关。

要点

  • 外科病房住院>24小时患者中,实验室警报可识别高死亡率人群,干预组总死亡率19.4% vs 对照组23.5%(p=0.50)。
  • 干预组首次实验室警报时RRT激活率10.7% vs 对照组2.0%(P<0.001),但联合健康转诊更少(18.0% vs 24.5%,p=0.007)。
  • 干预组后续警报前24小时内RRT激活更少(18.4% vs 22.4%,p=0.008),进一步警报更少(204 vs 320,p<0.001)。
  • 干预组更易在后续警报前24小时内获得不予复苏或气管插管状态(26.6% vs 17.3%,p=0.05)。
  • 24小时死亡率干预组1.9% vs 对照组2.9%(p=0.63),总死亡率19.4% vs 23.5%(p=0.50),均无显著差异。

适用人群与场景

  • 外科病房住院超过24小时的患者,来自三级医院外科病房。

诊断标准与关键阈值

  • 使用先前验证的风险评估工具对每套常规实验室检查进行评估以识别高危患者并生成「实验室警报」。

处置流程与药物剂量

  • 对实验室警报患者随机分配接受早期ICU团队复查(干预组)或常规照护(对照组)。

研究设计与关键结果

  • 前瞻性初步随机对照试验,纳入205例患者(男性54.1%,平均年龄79岁),干预组103例,常规照护组102例。
  • 干预组首次警报时RRT激活率10.7% vs 对照组2.0%(P<0.001),联合健康转诊18.0% vs 24.5%(p=0.007)。
  • 干预组后续警报前24小时内RRT激活18.4% vs 22.4%(p=0.008),进一步警报数204 vs 320(p<0.001)。
  • 干预组后续警报前24小时内不予复苏或气管插管状态26.6% vs 17.3%(p=0.05)。
  • 24小时死亡率干预组1.9% vs 对照组2.9%(p=0.63),总死亡率19.4% vs 23.5%(p=0.50)。

证据类型、等级与局限

  • 证据类型:前瞻性初步随机对照试验(pilot randomized controlled trial)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为在外科患者中实验室警报可识别高死亡率患者,警报触发的干预与更多首次警报相关RRT激活、更多向保守复苏状态转变、更少后续警报相关RRT激活、更少后续警报及更少联合健康干预相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

AIM: Common blood tests can help identify patients at risk of death, unplanned intensive care unit (ICU) admission, or rapid response team (RRT) call. We aimed to test whether early ICU-team review triggered by such laboratory tests (lab alert) is feasible, safe, and can alter physiological variables, clinical management, and clinical outcomes.

METHODS: In prospective pilot randomized controlled trial in surgical wards of a tertiary hospital, we studied patients admitted for >24 h. We applied a previously validated risk assessment tool to each set of common laboratory tests to identify patients at risk and generate a "lab-alert". We randomly allocated such lab-alert patients to receive early ICU-team review (intervention) or usual care (control).

RESULTS: We studied 205 patients (males 54.1%; average age 79 years; 103 randomized to intervention and 102 to usual care). Intervention patients were more likely to trigger RRT activation during their first lab-alert (10.7 vs. 2.0%; P < 0.001) but less likely to receive an allied health referral (18.0% vs. 24.5%; p = 0.007). They were less likely to trigger RRT activation in the 24-h before subsequent alerts (18.4 vs. 22.4%; p = 0.008) and less likely to generate further alerts (204 vs. 320; p < 0.001), but more likely to receive a not for resuscitation or endotracheal intubation status in the 24-h before subsequent alerts (26.6 vs. 17.3%; p = 0.05). Mortality at 24 h was 1.9% for the intervention group vs. 2.9% in the control group (p = 0.63). Finally, overall mortality was 19.4% for intervention patients vs. 23.5% for control patients (p = 0.50).

CONCLUSION: Among surgical patients, lab alerts identify patients with a high mortality. Lab alert-triggered interventions are associated with more first alert-associated RRT activations; more changes in resuscitation status toward a more conservative approach; fewer subsequent alert-associated RRT activations; fewer subsequent alerts, and decreased allied health interventions (ANZCTRN12615000146594).

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Bellomo R, Chan M, Guy C, et al. Laboratory alerts to guide early intensive care team review in surgical patients: A feasibility, safety, and efficacy pilot randomized controlled trial. Resuscitation. 2018. PMID: 30316952. doi:10.1016/j.resuscitation.2018.10.012

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。